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Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a
potential biomarker for Parkinson’s disease
Aims: Gastrointestinal (GI) a-synuclein (aSyn) detection
as a potential biomarker of Parkinson’s disease (PD) is
challenged by conflicting results of recent studies. To
increase sensitivity and specificity, we applied three
techniques to detect different conformations of aSyn in
GI biopsies obtained from a longitudinal, clinically well-
characterized cohort of PD patients and healthy con-
trols (HC). Methods: With immunohistochemistry
(IHC), we used antibodies reactive for total, phosphory-
lated and oligomeric aSyn; with aSyn proximity liga-
tion assay (AS-PLA), we targeted oligomeric aSyn
species specifically; and with paraffin-embedded tissue
blot (AS-PET-blot) we aimed to detect fibrillary, synap-
tic aSyn. Results: A total of 163 tissue blocks were col-
lected from 51 PD patients (113 blocks) and 21 HC
(50 blocks). In 31 PD patients, biopsies were taken
before the PD diagnosis (Prodromal); while in 20 PD
patients biopsies were obtained after diagnosis (Mani-
fest). The majority of tissues blocks were from large
intestine (62%), followed by small intestine (21%),
stomach (10%) and oesophagus (7%). With IHC, four
staining patterns were detected (neuritic, ganglionic,
epithelial and cellular), while two distinct staining pat-
terns were detected both with AS-PLA (cellular and dif-
fuse signal) and with AS-PET-blot (aSyn-localized and
pericrypt signal). The level of agreement between differ-
ent techniques was low and no single technique or
staining pattern reliably distinguished PD patients (Pro-
dromal or Manifest) from HC. Conclusions: Our study
suggests that detection of aSyn conformational variants
currently considered pathological is not adequate for
the diagnosis or prediction of PD. Future studies utiliz-
ing novel ultrasensitive amyloid aggregation assays
may increase sensitivity and specificity.
Keywords: Alpha-synuclein, Biomarker, Gastro-intestinal tract, Immunohistochemistry, Parkinson’s disease,
Prodromal
Introduction
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disease and a major cause of disabil-
ity and socio-economic burden. Currently, the diagnosis
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of PD rests on clinical criteria and can only be con-
firmed with a postmortem examination of the brain,
which reveals intraneuronal inclusions of misfolded
a-synuclein (aSyn) protein as Lewy pathology coupled
with neuronal loss in the substantia nigra (SN) [1]. In
vivo diagnostic biomarkers of PD are currently lacking
and could help to identify individuals at a preclinical
stage, possibly preceding significant neuronal loss in
the SN. PD biomarkers would potentially allow us to
identify subjects at risk, monitor disease progression,
optimize patient inclusion into clinical trials and help
us to assess the efficacy of future therapies [2].
Accumulation of aSyn is not limited to the central
nervous system (CNS) and we have recently reviewed a
growing body of literature showing that aSyn aggrega-
tion can be detected particularly in the enteric nervous
system (ENS) in postmortem but also in readily and
safely accessible in vivo biopsies of the gastro-intestinal
(GI) tract [3]. Some studies suggest that aSyn pathol-
ogy may start and be detectable in the GI tract in the
prodromal phase of PD perhaps before affecting the
brain [4–7], suggesting that GI aSyn detection could be
used as a predictive biomarker. According to a recent
popular hypothesis, the misfolding of aSyn initially
occurs in the ENS as a result of some environmental or
genetic insult that then further spreads to CNS via
vagal preganglionic innervation of the gut [8]. This
theory has been supported by in vivo evidence showing
the progression of pathology from the periphery to the
CNS following intramuscular [9] and gastric [10] injec-
tion of aSyn fibrils as well as vagotomy being associ-
ated with a decreased risk of PD [11].
It has, however, become increasingly apparent that the
high sensitivity and specificity of GI aSyn detection to iden-
tify PD patients reported in the earlier studies [12–16] has
not been sustained in subsequent studies repeatedly detect-
ing aSyn accumulation also in the GI tract of neurologi-
cally healthy individuals [17–21]. This was also confirmed
by a recent multicentre study, which showed limited diag-
nostic value for detecting aSyn deposition in the GI biop-
sies by immunohistochemistry (IHC) [22]. Noticeably,
heterogeneity of antibodies, antigen retrieval methods,
and sites of the GI tract assessed has produced significant
variability in morphological patterns, which has con-
founded interpretation of what is pathological compared
to nonspecific (or possibly physiological) staining.
This study was designed to tackle the limitations and
issues emerging from previous studies on GI aSyn
detection as a potential biomarker for PD. We detected
aSyn in paraffin-embedded GI biopsies from longitudi-
nally followed PD patients and healthy controls (HC)
participating in the Oxford Discovery study [23] using
three different techniques: conventional IHC, our
recently developed Proximity Ligation Assay for aSyn
(AS-PLA) [24] and Paraffin Embedded Tissue Blot for
aSyn (AS-PET-blot) [25]. Each technique is specific for
a particular variant or conformation of aSyn. For IHC,
antibodies reactive for total (T-aSyn-Ab) and phospho-
rylated (P-aSyn-Ab) aSyn were selected as they have
been most widely used for the detection of aSyn in the
GI tract making our results comparable with these pre-
vious studies [4,14,15,17,19,20]. We also used
recently developed antibodies specific for the oligomeric
forms of aSyn (O-ASN-Abs) [26], as transformation of
monomeric aSyn to oligomeric conformations is
increasingly recognized as the early, key pathological
event in the fibrillization process of aSyn [27]. With
AS-PLA [24], we targeted oligomeric aSyn and with
AS-PET-blot fibrillar, synaptic aSyn, neither which can
be detected with conventional IHC. Furthermore, we
focused to describe in detail what kind of morphological
staining patterns we could detect with each technique
and whether we interpreted them as pathological or
nonspecific. Finally, we reported each staining pattern
in the GI biopsies taken both prior and after the clinical
diagnosis of PD in order to see if they had predictive or
diagnostic value as biomarkers.
Methods
Subjects
The Discovery cohort (http://opdc.medsci.ox.ac.uk) of
the Oxford Parkinson’s Disease Centre (OPDC) is cur-
rently one of the largest and best-characterized longitu-
dinal cohorts of PD subjects and HC in the world
[23,28]. Full details of the protocols have been
described previously [29]. Briefly, validated question-
naires were used to assess and quantify a range of clin-
ical items in this cohort including: motor function
(MDS UPDRS part III); cognitive impairment (MMSE);
constipation (Honolulu-Asia Ageing Study Constipation
Questionnaire); hyposmia (the 16-stick Sniffin odour
identification test); RBD (Epworth Sleepiness Scale and
RBD Screening Questionnaire). All participants were
systematically screened for previous biopsies of the GI
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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tract after ethics committee approval and informed con-
sent obtained prior to tissue request and retrieval.
According to whether the biopsy had been performed
before or after clinical diagnosis of PD, PD cases were
classified as either ‘Prodromal PD’ or ‘Manifest PD’,
respectively.
Gastrointestinal Biopsies
Study specimens were residual tissue from biopsies or
surgical resections (e.g. polyps, cancer screening) from
various regions of the GI tract, including large and
small intestine, stomach and oesophagus. 5 lm-thick
sections were stained with routine haematoxylin and
eosin for standard histopathological evaluation by a
neuropathologist (JA) to confirm the anatomical local-
ization and quality of the specimens. Any biopsies con-
sisting entirely or predominantly of abnormal tissue
(e.g. carcinoma) were excluded.
Immunohistochemistry
Three different antibodies reactive for aSyn were applied
with optimized antigen retrieval (AR) procedures:
KM51, reactive against total length of aSyn 1-140
(Novocastra, 1:1000, AR with autoclave in citrate buf-
fer pH 6.0 followed by 10 min incubation in 99% for-
mic acid); pSyn#64, reactive against phosphorylated
aSyn at serine 129 (WAKO, 1:10 000, AR with 5 min
incubation in 20ug/ml PK); O2, reactive to fibrillary
and oligomeric aSyn conformations (gift from Dr El-
Agnaf, 1:10.000, AR with autoclave in citrate buffer
pH 6.0). To detect and quantify nervous tissue, two
antibodies were used; Anti-Calretinin (5A5, Novocastra,
1:200) and Anti-Hu C/D (Thermofisher, 1:1000); with
autoclave-based, heat-mediated AR in citrate buffer (pH
6.0) for both. For detection, Dako REALTM EnVisionTM
Detection System was used with diaminobenzidine as
chromogen. Assessment of aSyn immunoreactivity
(absence/presence and immunostaining pattern) was
carried out by two observers independently (CR, LP)
without knowledge of the clinical history or diagnosis.
Proximity ligation assay
AS-PLA was carried out using Duolink in situ detec-
tion kit (Sigma) according to the manufacturer’s
instructions. Briefly, the conjugates were prepared
using the Duolink Probemaker kit by incubating
20 ll of mouse 211 anti-alpha-synuclein antibody
(ab80627, Abcam) with the Probemaker activated
oligonucleotide (+ or -) and conjugation buffer over-
night at room temperature (RT). The conjugates were
then incubated with Probemaker stop reagent for
30 min at RT and suspended in Probemaker storage
buffer and stored at +4°C. 5 lm-thick paraffin-
embedded sections were dewaxed in xylene and rehy-
drated in graded ethanol series. AR was carried out
with autoclave in citrate buffer pH 6.0 followed by
blocking endogenous peroxidases with hydrogen perox-
ide for 15 min at RT. For coimmunofluorescence, sec-
tions were blocked in 10% normal goat serum, 1 M
glycine TBS + 0.1% Triton and incubated for 1 h in
primary antibody; Calretinin (5A5, Novocastra, 1:100),
washed with TBS + 0.1% Triton and incubated for 1 h
in the dark with Alexa488 (Life Technologies). Sections
were washed in TBS + 0.1% Tween 20 (TBS-T) and
incubated in Duolink block solution at 37°C for 1 h,
followed by the conjugates diluted in Duolink PLA
probe diluent (1:100) overnight at 4°C. After washing
in TBS-T, sections were incubated with Duolink liga-
tion solutions and ligase for 1 h at 37°C followed by
Duolink amplification reagents and polymerase for
2.5 h at 37°C. For fluorescence, sections were washed
in the dark and counterstained with DAPI 1:1000 and
mounted with FluorSave (Millipore). For brightfield,
sections were washed and incubated with Duolink
detection solution for 1 hr at RT followed by Duolink
substrate solution for 20 min at RT. Each step was fol-
lowed by washes in TBS-T (3 9 5 min). Sections were
then counterstained with haematoxylin (Vector labs)
and dehydrated in graded ethanol series and xylene,
before mounting with DPX mounting reagent (Sigma).
All fluorescent images were acquired with an EVOS
FL autoimaging system at 920 magnification and auto-
matically analysed with Cell Profiler for nuclear DAPI
counting. ImageJ was used for the automatic quantifi-
cation of AS-PLA-positive diffuse puncta and double-
labelled AS-PLA and Calretinin-positive cells were
counted manually (NBV) blinded to the clinical diagno-
sis. Four random images were taken and analysed in
order to provide a representative sampling of the tissue.
Counts are expressed as average AS-PLA-positive dif-
fuse puncta/AS-PLA+calretinin-positive cellular counts
relative to the number of nuclei present in each
imaging field.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Paraffin embedded tissue blot
5 lm-thick paraffin-embedded sections were blotted
onto 0.45 lm pore-size nitrocellulose membranes (Bio-
rad) and dried at 55°C for 24 h to improve adhesive-
ness of the tissue to the membrane. Sections were then
dewaxed in xylene followed by rehydration in propanol
series progressively diluted in distilled water (dH2O)
(100%, 95%, 85%, 70%) and finally in dH2O. Sections
were then dried for at least 4 h, excess membrane
around the area with blotted tissue cut and sections
placed into six-well plates. Sections were incubated in
TBS-T for 30 min followed by incubation in PK
(50 lg/ml) at 55⁰C for 3 h according to our optimized
protocol. After PK incubation, sections were washed in
TBS-T (3 9 5 min) and incubated in denaturing buffer
containing 3M Guanidine isothiocyanate followed by
further washes with TBS-T (3 9 5 min) and blocking
with casein (Vector Laboratories) for 30 min. Samples
were then incubated overnight at RT with primary
antibody; LB509 (Millipore, 1:10 000). After washing
with casein (3 9 5 min), sections were incubated with
secondary anti-mouse biotinylated antibody (1:1000)
for 1 h, washed again with casein (3 9 5 min), and
then incubated with avidin-biotin complex (Vectastain
ABC-AmP, Vector Laboratories) for 25 min. After fur-
ther washes with casein (3 9 5 min), labelling was
developed using alkaline phosphatase BCIP/NBT solu-
tion (Vector Laboratories). All incubations were carried
out on a shaking table (except for PK incubation in the
oven) with 5 ml solution/well. Finally, sections were
abundantly rinsed in distilled water. After air-drying,
sections were briefly dipped in xylene and mounted
using DPX mounting reagent (Sigma), which enabled
visualization with a normal light microscope. Digital
images of slides at 940 magnification were obtained
using Aperio Scanscope and each blot was examined
by two observers (IP, CR) without knowledge of the
clinical history or diagnosis.
Statistical analysis
Univariate comparisons between two groups (PD vs
HC) were made using the t-test or Fisher’s exact test/
Chi-square. For comparisons between three groups
(Prodromal PD, Manifest PD, and HC), we used
one-way ANOVA or Fisher’s exact test/Chi-square. We
used t-test, ANOVA and Pearson or nonparametric
Mann–Whitney, Kruskal–Wallis and Spearman to eval-
uate relationship and correlations between clinical,
demographic and pathological variables of interest. The
measure of agreement between categorical assessments
of the two techniques was estimated applying the
Cohen kappa. Receiver Operator Characteristic (ROC)
curves were constructed to evaluate the ability of
pathology to predict the clinical status.
Results
Clinical and demographic characteristics
Demographic and clinical information is given in
Table 1. In the overall cohort, the mean age at biopsy
was 65.3  9.9 years. Thirty-one PD subjects were
classified as ‘Prodromal PD’, and in this group the
mean time from biopsy to PD diagnosis was
5.8  3.8 years. In the 20 ‘Manifest PD’ patients, the
mean time from PD diagnosis to GI biopsy was
1.6  1.4 years. The ‘Manifest PD’ group was signifi-
cantly older at the time of biopsy compared to both
‘Prodromal PD’ cases (P = 0.007) and HC (P = 0.015).
The mean age at PD diagnosis was 69.1  8.2 years
and did not differ between the ‘Prodromal’ and ‘Mani-
fest’ PD groups. The earliest GI biopsy was performed
Table 1. Demographic and clinical characteristics across the
clinical groups
Prodromal
PD
Manifest
PD
Healthy
Controls P-value
N 31 20 21 –
Males 16 (52) 13 (65) 7(33) 0.140
Age at biopsy 63 (43–83) 71 (57–85) 62 (39-86) 0.014
Age at
diagnosis
69 (56–87) 69 (55–83) – 0.342
Biopsy –
Diagnosis
6 (1–17) 2 (5–0) – <0.001
UPDRS III 26 (6–41) 35 (14–68) 3 (0–10) <0.001
MMSE 28 (23–30) 28 (20–30) 29 (24–30) 0.181
MOCA 24 (16–30) 24 (17–29) 27 (21–30) 0.036
Constipation 17 (57) 4 (22) 7 (33) 0.045
RBD 16 (52) 8 (42) 4 (20) 0.077
Hyposmia 21 (68) 13 (72) 3 (15) <0.001
Probability
PD
90 90 – 0.991
Values are presented as number of cases, with range or % in
parenthesis, as appropriate. Groups were compared with one-way
ANOVA, independent samples T-test or Chi-Square test, as appro-
priate. Numbers in bold represent significant differences between
groups.
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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17 years prior to the diagnosis of PD, while the longest
duration of disease at the time of GI biopsy was
5 years.
The UPDRS motor score was significantly higher in
the ‘Manifest PD’ compared to ‘Prodromal PD’
(P = 0.005) and in both PD groups compared to
HC (P < 0.001). The MOCA scores were significantly
lower in both ‘Manifest PD’ (P = 0.017) and ‘Prodro-
mal PD’ (P < 0.001) compared to HC but did not differ
between two PD groups. There were no significant dif-
ferences amongst the three groups in MMSE. Preva-
lence of constipation was significantly different
(P = 0.045); being highest in the ‘Prodromal PD’ (pre-
sent in 57%), followed by HC (present in 33%) and
‘Manifest PD’ (present in 22%). Prevalence of hyposmia
was also statistically different (P < 0.001); seen equally
in ‘Manifest PD’ (72%) and ‘Prodromal PD’ (68%),
whereas only 15% of HC suffered from a loss of smell.
There were no differences in prevalence of REM sleep
behaviour disorder (RBD) and probability of PD.
Gastrointestinal tissue biopsies
We retrieved a total of 113 tissue blocks from 51 PD
patients and 50 blocks from 21 HC, from ~200 Discov-
ery participants declaring a previous GI biopsy. Recall
bias or colonoscopy being done without any sampling
explained the missing biopsies. Staining was performed
on tissue sections from one or more GI tract regions
from 72 subjects (51 PD and 21 HC). A single GI
region was examined in 53 cases (38 PD and 15 HC),
two regions in 13 cases (9 PD and 4 HC) and three
regions in six cases (4 PD and 2 HC). Large bowel was
studied in 101 blocks (35 PD and 12 HC), small bowel
in 34 (19 PD and 10 HC), stomach in 12 (7 PD and 5
HC), and oesophagus in 11 (7 PD and 2 HC).
Immunohistochemistry
Neuronal staining Semiquantitative assessment of the
intensity of staining (i.e. absent to intense) with the
neuronal marker (calretinin/Hu) was carried out to
estimate the density of nervous tissue, including
mucosal nerve fibres and submucosal ganglionic
neurones (Table 2, Figure 2E–G). There were no
significant differences in the neuronal score of GI
biopsies or in the prevalence of submucosal ganglionic
neurones between PD and HC.
aSyn staining All cases had at least one tissue block
stained with each of the three antibodies reactive for
aSyn. Overall positive staining for aSyn IHC was found in
GI tissue sections of 31/51 (61%) PD patients (21
Prodromal and 10 Manifest) and 13/21 (62%) HC.
Several different staining patterns were observed
(Figure 1). Two of these were suggestive of neuronal
localization of aSyn: neuritic-like distribution in the
mucosa (neuritic staining, Figures 1A, 2A) and diffuse/
granular pattern seen inside the submucosal ganglionic
cells (ganglionic staining, Figures 1B, 2C) that often
colocalized with our neuronal marker in adjacent sections
(Figures 2B,D). Diffuse, dense staining in the myenteric
plexus was also seen in the few cases where this was
present in the biopsy (Figure 1C). Other types of staining
observed in a significant proportion of cases, on the other
hand, were suggestive of a non-neuronal localization.
The most prevalent of this type of staining was found in
the cytoplasm of epithelial cells lining the gastric glands
of the mucosa, (epithelial staining, Figure 1D,E) or in
other cellular components of the mucosa (cellular
staining, Figure 1F). In a small number of cases, further
staining patterns were also observed, including lacy-
granular staining (Figure 1G), perivascular staining
(Figure 1H) and aSyn-positive macrophages (Figure 1I).
These were, however, very rare and judged to be
nonspecific staining (not included in further analysis).
Different antibodies showed varying sensitivities
towards different staining patterns observed. The stain-
ing was most prevalent with the O-aSyn-Ab, which
detected any neuronal (neuritic/ganglionic) staining in
13 of 31 (42%) Prodromal PD patients; 7 of 20 (35%)
Manifest PD patients and 5 of 21 (24%) HC. The P-
aSyn-Ab revealed neuronal staining in 4 of 31 (13%)
Prodromal PD patients; 3 of 20 (15%) Manifest PD
patients and 5 of 21 HC (24%), whereas the T-aSyn-Ab
Table 2. Baseline histological characteristics of the GI biopsies
PD HC P-value
Semiquantitative neuronal score:
0 (none) 24% 22% 0.451
1 (some) 25% 17%
2 (moderate) 37% 36%
3 (severe) 14% 25%
Submucosa present (Y/N) 47% 61% 0.143
Submucosal ganglia present (Y/N) 28% 35% 0.449
Number of submucosal ganglia (Total) 64 43 0.129
Myenteric plexus present (Y/N) 8% 11% 0.525
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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revealed no positive neuronal staining in any of the
examined cases. Interestingly, the T-aSyn-Ab showed
aSyn staining in only three subjects, with cellular-like
staining in the mucosa in 2 PD patients and an epithe-
lial pattern in one HC.
When we compared the prevalence of various stain-
ing patterns between PD and HC and between Prodro-
mal PD, Manifest PD and HC groups using any of our
three antibodies, there were no statistically significant
differences (Table 3), even when the four HC subjects
with RBD were removed from analysis. Grouped neu-
ronal (neuritic or ganglionic) or non-neuronal (epithelial
or cellular) staining also did not differ between the
groups. ROC curve analysis showed that neither the
neuronal or non-neuronal staining were accurate pre-
dictors of the clinical status (AUC = 0.578 for neu-
ronal, AUC = 0.501 for non-neuronal staining).
Furthermore, none of the clinical variables (UPDRS,
MMSE, MOCA, constipation, RBD, hyposmia) were sta-
tistically different in the group with GI aSyn neuronal
staining compared to the group without. When preva-
lence of aSyn staining was compared by presence or
absence of submucosa in the tissue sample, there was a
significantly higher prevalence of aSyn staining in the
group with submucosa, which is not surprising. How-
ever, when we included only samples with submucosa
available, there was no significant difference in preva-
lence of aSyn staining between PD and HC groups.
There was no correlation between age at biopsy and
prevalence of aSyn staining.
Analysis of IHC staining patterns by GI region did
reveal significant differences in their distribution
(P < 0.001); there was significantly more neuronal
aSyn staining in the small bowel (47%) followed by
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
Figure 1. Photomicrographs of aSyn staining patterns with immunohistochemistry: Neuritic (A); Ganglionic (diffuse/granular) (B);
Myenteric (C); Epithelial (D, E); Cellular (F); Lacy-Granular (G); Perivascular (H); Macrophages (I).
© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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oesophagus (27%) compared to stomach and large
bowel (both 13%). The prevalence and intensity of
non-neuronal staining was much greater in the distal
GI tract (i.e. small and large bowel) and was not found
in the oesophagus or stomach (Table 4).
Proximity ligation assay
104 blocks were stained from 58 individuals (40 PD
and 18 HC) for AS-PLA. Immunofluorescent AS-PLA
was optimized in order to achieve a comparable signal
to brightfield AS-PLA followed by double immunola-
belling with the neuronal marker calretinin. Two types
of staining were detected with AS-PLA-calretinin double
immunofluorescence: (i) cellular-like formations in the
mucosa, which partly costained with the neuronal mar-
ker calretinin (i.e. cellular signal) and (ii) a dot-like pat-
tern detected throughout the section, with no specific
anatomic localization (i.e. diffuse signal) (Figure 3). AS-
PLA cellular signal was statistically higher in the group
(A) (B)
(C)
(E) (F) (G)
(D)
Figure 2. aSyn-reactive antibodies revealed neuritic-like pattern in the mucosa (A) and diffuse, intraneuronal staining of some
submucosal ganglionic neurones (C) which resembled the morphological pattern of staining obtained with the neuronal marker
(calretinin) in consecutive sections (B, D). Semiquantitative grading of neuronal marker, calretinin. 1 = Low density of nerve fibres; no
ganglionic cells (E); 2 = Low density of nerve fibres and ≥ 1 ganglionic cell, or moderate-high density of nerve fibres without ganglionic
cells (F); 3 = Moderate-high density of nerve fibres and ≥ 1 ganglionic cell (G). Magnification 9100 A, B, F and 9200 in C, D, E, G.
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with high neuronal score compared to low (P = 0.008)
and correlated significantly with the number of
ganglia/section (P = 0.026). However, the level of
agreement between neuronal aSyn IHC staining and
cellular AS-PLA signal (which we divided into low and
high by a mean value of 0.02) was poor (P = 0.095,
j = 0.04), with 41% (43/104) of all blocks showing a
contradictory result in terms of aSyn positivity.
In 104 blocks, the mean score for the cellular and dif-
fuse AS-PLA signals were 0.02  0.02 and
0.66  0.50, respectively, but there were no significant
differences in either signal between any of the study
groups (Table 3, Figure 3C-D). Furthermore, the two dif-
ferent types of AS-PLA staining did not correlate with
each other. ROC curve analysis showed that neither sig-
nal was a reliable predictor of the clinical status
(AUC = 0.737 for cellular and AUC = 0.597 for diffuse
AS-PLA signal). Neither AS-PLA signal correlated with
UPDRS motor score or MMSE but the cellular AS-PLA
signal (not diffuse) correlated positively with MOCA
(P = 0.030, rs = 0.288). AS-PLA cellular/diffuse signals
were not significantly different in subjects who were
Table 3. Prevalence of staining patterns across the clinical groups
PD Prodromal PD Manifest PD HC
PD vs. HC
(P-value)
Prodromal PD vs.
Manifest PD vs.
HC (P-value)
Number 51 31 20 21
aSyn IHC Neuronal
Neuritic (mucosal) 18 (35) 10 (32) 8 (40) 4 (19) 0.174 0.334
Ganglionic (submucosal) 14 (27) 8 (26) 6 (30) 7 (33) 0.499 0.838
Any neuronal (neuritic
or ganglionic)
25 (49) 16 (52) 9 (45) 7 (33) 0.441 0.428
aSyn IHC Non-Neuronal
Epithelial 18 (35) 13 (42) 5 (25) 10 (48) 0.330 0.299
Cellular 9 (18) 4 (13) 5 (25) 2 (10) 0.384 0.344
AS-PLA*
Cellular 0.02  0.03 0.02  0.04 0.02  0.02 0.02  0.02 0.737 0.716
Diffuse 0.69  0.49 0.65  0.51 0.74  0.48 0.76  0.50 0.597 0.662
AS-PET-blot
aSyn-localized 9 (18) 5 (16) 4 (20) 8 (38) 0.063 0.170
Pericrypt 30 (59) 19 (61) 11 (55) 12 (57) 0.217 0.423
Values are presented as numbers and (% within clinical subgroup) except AS-PLA Diffuse and Cellular variables, which are presented as
mean score  SD.
*Group comparison carried out with nonparametric Mann–Whitney or Kruskal–Wallis test.
Table 4. Prevalence of different staining types across different GI regions
Oesophagus Stomach Small Bowel Large Bowel P-value
aSyn IHC Neuronal (n) 11 16 34 102
Neuritic (mucosal) 3 (27) 2 (13) 11 (32) 2 (2) <0.001
Ganglionic (submucosal) 0 1 (6) 11 (32) 11 (11) 0.004
Any neuronal (neuritic or ganglionic) 3 (27) 2 (13) 16 (47) 13 (13) <0.001
aSyn IHC Non-Neuronal (n) 11 16 34 102
Epithelial 0 0 14 (41) 20 (20) 0.001
Cellular 0 0 3 (9) 11 (11) 0.391
AS-PLA* (n) 5 9 27 63
Cellular 0.04  0.08 0.01  0.01 0.02  0.02 0.02  0.02 0.020
Diffuse 0.86  0.53 0.89  0.49 0.58  0.39 0.65  0.54 0.239
AS-PET-blot (n) 5 5 23 56
aSyn-localized 0 0 7 (30) 10 (18) 0.228
Pericrypt 2 (40) 2 (40) 10 (43) 34 (61) 0.479
Values are presented as number of positive blocks (% of all the block stained of the GI region).
*Group comparison carried out with nonparametric Kruskal–Wallis test. Numbers in bold represent significant differences between groups.
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constipated or had hyposmia compared to subjects who
did not present with these symptoms. However, the
mean diffuse AS-PLA signal was found statistically
higher (P = 0.020) in subjects without RBD
(0.84  0.51) than with RBD (0.54  0.42).
The cellular AS-PLA signal was statistically higher in
the large (P = 0.038) and small bowel (P = 0.012)
compared to stomach, in small bowel compared to
oesophagus (P = 0.024) (Figure 3E). The diffuse AS-
PLA signal showed no differences with regard to GI
tract distribution (Table 4, Figure 3F).
Paraffin-embedded tissue blot
89 blocks were stained with the AS-PET-blot technique
from 51 PD patients and 21 HC, so that at least one
tissue block was stained from each case. This method
was first optimized using brain tissue and revealed
numerous aSyn micro-aggregates in the striatum of a
PD patient that were not detected with conventional
IHC. The most frequently occurring signal we observed
with this technique in GI biopsy tissue was present in
more than half (55%) of the examined blocks and con-
sisted of staining along the borders of the mucosal
glands or crypts (pericrypt staining, Figure 4E–F).
Another type of staining occasionally colocalizing with
aSyn deposition detected with IHC (aSyn-localized stain-
ing, Figure 4A–D) was observed in 17 (19%) out of 89
examined blocks. Despite the partial colocalization, the
level of agreement between neuronal aSyn IHC staining
and PET-blot aSyn-localized signal was poor
(P = 0.709, j = 0.04), with 34% (30/89) of all blocks
showing a contradictory result in terms of aSyn positiv-
ity. Furthermore, no statistical differences in either
(A) (B)
(C) (D)
(E) (F)
Figure 3. AS-PLA (red) – calretinin (green) double immunofluorescence detected two types of staining (A) cellular signal i.e. cellular -like
formations in the mucosa partly costained with the neuronal marker calretinin; (B) diffuse signal i.e. a dot-like pattern detected
throughout the section without any specific anatomic localization. Magnification 9100 in A, 9200 in B. CTRL: Control; ES: Oesophagus;
LB: Large Bowel; PD: Parkinson’s Disease; SB: Small Bowel; ST: Stomach.
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pericrypt or aSyn-localized staining patterns were found
between the study groups (Table 3). ROC curve analy-
sis showed that aSyn-localized PET-blot signal was not
a reliable predictor of the clinical status (AUC = 0.398).
In contrast, the UPDRS score was significantly lower
(P = 0.020) among those cases that showed the aSyn-
localized staining (13  12) compared to ones without
(24  17). There were no differences in MMSE score,
but MOCA was also significantly higher (P = 0.020)
among the cases with aSyn-localized staining (27  2)
compared to ones without (25  3). The prevalence of
aSyn-localized signal was not significantly different in
relation to constipation, RBD or hyposmia and showed
no difference with regard to GI tract distribution.
Discussion
In this study, we approached detection of aSyn in the
ENS as a potential biomarker for PD, with the goal of
increasing sensitivity and specificity and gaining a bet-
ter understanding of early pathogenic mechanisms in
the PD GI tract. IHC, AS-PLA and AS-PET-blot were
applied, each targeting a specific conformational/post-
translational variant of aSyn, namely (i) total (mono-
meric), (ii) phosphorylated, (iii) oligomeric and (iv)
synaptic, fibrillar aSyn. We described the morphological
staining patterns detected with each technique and
their possible interpretation as pathological.
With IHC, positive aSyn staining was found in 61%
of PD patients and in 62% of HC. Putatively pathologi-
cal neuronal aSyn staining was detected in a smaller
proportion of subjects but again with no significant dif-
ference between PD (49%) and HC (33%). Thus, simi-
larly to other studies examining sizeable archived
biopsy samples [4,6], the sensitivity of neuronal aSyn
staining was poor. Furthermore, unlike others [14], we
found no relationship between neuronal aSyn staining
and any of our detailed clinical features (motor and
(A) (B)
(C)
(E) (F) (G)
(D)
Figure 4. Some aSyn-positive PET-blot staining (B, D) colocalized with staining observed with immunohistochemistry (A, C). Pericrypt
AS-PET-blot signal in colonic tissue of Parkinson’s disease patient at low 940 (E) and high 9200 (F) magnification. Absence of a similar
signal in colonic tissue of another PD case (G). Magnification 910 in A, B 100 9 in C, D. Antibodies: IHC - O2; PET-Blot – LB509.
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cognitive scores, constipation, RBD, hyposmia). Inter-
estingly, neuronal aSyn pathology was recently found
in colonic biopsies of 4 out of 17 (24%) patients with
RBD [7], who carry an 80% risk of developing synucle-
inopathy [30]. The earliest time point we detected any
neuronal aSyn pathology was 10 years before the
development of clinically manifesting PD, but no differ-
ence was seen between ‘Prodromal PD’ (52%) vs. ‘Man-
ifest PD’ (45%) groups, suggesting that there is no
cumulative effect over time. With regards to clinico-
pathological correlation, it must be noted that there
was significant variability in the time lag between
biopsy date and the time of clinical characterization,
thus this correlation has potentially limited relevance.
In a small number of cases, more than one GI region
was studied. While this was not systematically assessed
in this study, comparing aSyn staining patterns
between different GI regions of the same subject could
address the issue of differential susceptibility to aSyn
accumulation and transmission.
The overall specificity in our study was 67% (i.e. 7 of
our 21 HC showed neuronal aSyn pathology). In previ-
ous studies, the specificity has ranged extensively from
near 100% [4,13–16] to 0% [17–19]. Varying sensitiv-
ity and specificity of aSyn antibodies recognizing differ-
ent epitopes is a well-described phenomenon in the
brain [31,32] but was recently also demonstrated in the
GI tract [33]. Harmonizing terminology used to describe
different morphological patterns of aSyn immunoreac-
tivity seen in the GI tract and their biological interpreta-
tion (pathological vs. nonspecific/physiological) is also
emerging [33,34]. Similar to a recent consensus paper
[34], we observed granular staining in the mucosa/lam-
ina propria, which we termed as neuritic, since it is sug-
gestive of localization in the peripheral nerve endings as
demonstrated by staining with the neuronal marker
(i.e. calretinin). In addition, roughly one-third of our
sections contained submucosa, where aSyn staining
was observed in the ganglionic cells with a diffuse or
granular pattern (defined as ganglionic) that also over-
lapped with the neuronal staining. Thus, both of these
staining patterns (i.e. neuritic and ganglionic) were con-
sidered to be specifically neuronal and putatively patho-
logical. Different antibodies showed drastically different
sensitivities (and specificities) for the neuronal pattern
of staining, with the highest sensitivity being achieved
with the O-aSyn-Ab, with a positive signal in 39%
of PD vs. 24% HC, followed by the P-aSyn-Ab with
14% of PD vs. 24% HC, and finally T-aSyn-Ab that
surprisingly, and in contrast with other studies
[4,15,19,20,33] showed no neuronal staining in any of
the examined cases. We found no difference in speci-
ficity whether we used O/P-aSyn-Ab. Although phos-
phorylation is generally considered a marker of choice
to delineate pathological aggregates from normal, native
aSyn accumulation [35], using the P-aSyn-Ab, Bottner
et al. [17] and Visanji et al. [19] detected neuronal aSyn
pathology in all of their HC. In another study, colonic
biopsies from PD and HC showed no difference in phos-
phorylated aSyn expression levels measured by Western
blotting [36]. These findings emphasize the need for a
better understanding of aSyn phosphorylation in PD
pathogenesis both in the brain and in the GI tract
[37,38]. Improved quantification of aSyn staining could
also benefit sensitivity and specificity. To date, studies
have mostly used qualitative assessment of sections to
define pathology, and only a few studies have attempted
quantification with semiquantitative grading scales to
measure the severity of staining [14,20,39]. Virtual
microscopy and whole-slide imaging could allow a more
robust quantitative analysis of enteric aSyn and poten-
tially facilitate definition of reliable cut-off scores to dis-
tinguish PD patients from controls.
In vivo endoscopic biopsies are willingly kept superfi-
cial for safety reasons (i.e. to prevent bleeding), and
consequently these specimens usually reveal dot/
thread-like aSyn deposits in the peripheral nerve end-
ings in the mucosa but rarely show ganglionic peri-
karyal inclusions. The empirical categorization as
pathological or not is based on morphological features
and double-labelling with neuronal markers, but the
encountered aSyn staining patterns are not always
easily traceable to a definite anatomic localization and
at times are suggestive of nonspecific, possibly even
artefactual staining. Indeed, in addition to neurons,
aSyn is physiologically expressed in hematopoietic [40],
endothelial and neuroendocrine cells [41] and in mus-
cle fibres [42]. We found several cases with staining of
epithelial cells of gastric glands that was considered to
be a nondisease-related cross-reaction to some secretory
protein or enzymes of the gastric mucosa [33]. Cellular
elements detected, on the other hand, could represent
mucosal macrophages ingesting pathological aSyn but
their role in PD pathogenesis remains to be established
[18]. Therefore, the detection of non-neuronal aSyn
does not necessarily indicate a disease state.
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Conversely, we cannot currently rule out the potential
pathogenic role of non-neuronal aSyn either. Indeed,
plasma cells, neuroendocrine and smooth muscle cells,
which are highly represented in the GI tract (as
opposed to the CNS) and located in close proximity to
neuronal elements, could represent possible sources of
aSyn be taken up by neurones, and further studies
assessing transport of aSyn between neuronal and non-
neuronal cells would be informative [3].
The PLA was developed for in situ detection of inter-
actions between different, functionally related proteins
through generation of a chromogenic or fluorescent
signal following DNA circularization and amplification
[43]. This technique was recently adapted by our group
to detect oligomeric forms of aSyn resulting from inter-
action of two or more aSyn monomers [24]. This is the
first study to have applied the AS-PLA for the detection
of aSyn oligomers in the GI tract, and we hypothesized
that we could detect these pathological aSyn conforma-
tions early, possibly at a prodromal PD stage. Of the
two types of AS-PLA signal that were observed, the cel-
lular staining positively correlated with neuronal score
and number of ganglionic neurones, which supports
the idea that this staining was localized mainly to neu-
ronal elements in the mucosa and submucosa. The dif-
fuse staining pattern we observed in the GI tract was
reminiscent of what is seen in the neuropil of the cor-
tex of PD patients that may represent synaptic distribu-
tion, but this needs to be examined further. While
AS-PLA did detect oligomeric aSyn in the majority of
sections stained, there was no distinctive pattern or
quantitative threshold that could distinguish between
PD patients (Prodromal or Manifest PD groups) and
HC. Furthermore, the cellular AS-PLA signal was actu-
ally found to be higher in the patients that performed
better in their cognitive testing and the diffuse AS-PLA
signal lower in those patients with RBD compared to
those without. Thus, clearly, the role of oligomeric
forms of aSyn in the GI tract needs further elucidation,
but it could be that these conformations are rather
transient and their quantification in a single time point
may not be a meaningful approach as a biomarker.
Finally, considering that aSyn aggregation likely
begins in the axon terminals (i.e. peripheral nerve end-
ings), we hypothesized that PET-blot would be ideal to
detect this early pathology in the GI tract. This protein
detection technique was originally developed to detect
pathological prion protein [44] and is based on the
incubation of paraffin-embedded tissue with proteinase
K (PK), a 28.9 KDa serine protease with broad speci-
ficity that digests proteins through cleavage of peptide
bonds. Importantly, the monomeric, physiological form
of aSyn is digested with PK treatment, whereas the
aggregates of misfolded and insoluble aSyn resist diges-
tion [45,46], increasing the visualization of smaller
aSyn micro-aggregates, that most likely represent
synaptic pathology [25,47]. Despite successful optimiza-
tion of AS-PET-blot in the PD brain to reveal striatal
aSyn micro-aggregates undetectable by conventional
IHC, we were unable to obtain a similar, specific signal
in the GI tissue. This could be due to several reasons,
such as that GI tissue has a different fat/soft/connective
tissue composition compared to CNS, and this may at
least partly explain the higher propensity of GI biopsy
tissue to be morphologically damaged by the PK treat-
ment. Our assessment of optimal PK concentrations,
incubation temperatures and durations in the GI tract
resulted in ‘softer’ conditions than those used in the
brain, which improved morphological quality of
the stained sections but may have also interfered with
the PET-blot’s ability to reveal the synaptic aSyn
microaggregates. It is also possible that aSyn conforma-
tions may differ between GI tract and brain, with the
former hosting a smaller proportion of fibrillary forms of
aSyn. Interestingly, some studies examining biochemical
characteristics of aSyn between the ENS and CNS have
shown that native aSyn occurs primarily as a monomer
in enteric neurones [22], whereas in the brain dimeric
and tetrameric species of aSyn are also observed [48].
These differences in aSyn conformations may explain
the discrepancy in our results with AS-PET-blot
between ENS and CNS. Similar to an earlier study by
Visanji et al. [19], we did observe coarser accumulations
of aSyn without specific morphological localization with
AS-PET-blot that partially colocalized with aSyn IHC in
adjacent sections; however, these did not allow distinc-
tion between PD and HC. In addition, no correlation
with severity of clinical symptoms was found, and in
contrast, the group with aSyn-localized PET-blot signal
performed better in both motor and cognitive testing
than the group without these changes in the GI tract.
Conclusions
In this study, for the first time, the GI tract was tar-
geted by three different methods, each specific for
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alternative conformations of aSyn, to increase speci-
ficity and sensitivity of detecting pathological GI aSyn
as a diagnostic biomarker for PD. However, although
we detected specific staining patterns with each
method, no single technique or staining pattern was
able to reliably distinguish PD patients (Prodromal or
Manifest PD) from HC. None of the pathological stain-
ing patterns correlated with severity of clinical symp-
toms; in contrast, some were more abundant in those
patients who performed better with their motor or cog-
nitive tests. Thus, our detailed description of aSyn
detection in GI biopsy tissue from a large, clinically
well-characterized cohort does not support any
predictive or diagnostic value for this approach. More
sensitive methods such as our recently developed aSyn
real-time quaking induced conversion (AS-RT-QuIC)
assay [49] may prove more helpful than tissue-based
detection techniques for different aSyn conformations.
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